{
    "eid": "2-s2.0-85144530385",
    "title": "Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Noppacharn Uaprasert",
        "Palada Pitakkitnukun",
        "Nuanrat Tangcheewinsirikul",
        "Thita Chiasakul",
        "Ponlapat Rojnuckarin"
    ],
    "citedby-count": 5,
    "ref-count": 197,
    "ref-list": [
        "COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)",
        "Hematologic malignancy patients suffer higher mortality and morbidity from COVID-19 than solid tumor patients",
        "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine",
        "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine",
        "Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19",
        "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK",
        "Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study",
        "Immunogenicity and risk of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis",
        "Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review",
        "CD8+T cells contribute to survival in patients with COVID-19 and hematologic cancer",
        "Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "Measuring in consistency in meta-analyses",
        "Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer",
        "Suboptimal response to Coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: A need for vigilance in the postmasking era",
        "Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma",
        "Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy",
        "Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma",
        "Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients",
        "Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia",
        "Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial",
        "Response to SARS-CoV-2 vaccination in patients with Multiple Myeloma using a 12-week spaced dosing strategy",
        "Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls",
        "Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience",
        "Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors",
        "Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies",
        "Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study",
        "Longitudinal SARS-CoV-2 mRNA vaccine-induced humoral immune responses in patients with cancer",
        "The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV-2 vaccine calls for a third dose",
        "Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies",
        "Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study",
        "Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies",
        "Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies",
        "Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies",
        "Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma",
        "BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies",
        "Serologic response to mRNA COVID-19 vaccination in lymphoma patients",
        "Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines",
        "Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients",
        "Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma",
        "CD19+IgD+CD27- naive B cells as predictors of humoral response to COVID 19 mRNA vaccination in immunocompromised patients",
        "Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies",
        "Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution",
        "Humoral and cellular vaccination responses against SARS-CoV-2 in hematopoietic stem cell transplant recipients",
        "Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia",
        "Antibody responses after a third dose of COVID-19 vaccine in kidney transplant recipients and patients treated for chronic lymphocytic leukemia",
        "Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia",
        "Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy",
        "Antibody response to COVID-19 vaccination in adults with hematologic malignant disease",
        "Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies",
        "Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis",
        "Cell-mediated and humoral immune response to 2-dose SARS-CoV2 mRNA vaccination in Immunocompromised patient population",
        "COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia",
        "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma",
        "Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma",
        "High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination",
        "Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer",
        "Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients",
        "Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment",
        "Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation",
        "SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group",
        "Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine",
        "Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood",
        "Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia",
        "Seroconversion rates following COVID-19 vaccination among patients with cancer",
        "Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination",
        "Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients",
        "Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients",
        "Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity",
        "BNT162b2 mRNA COVID-19 vaccine booster induces seroconversion in patients with B-cell non-Hodgkin lymphoma who failed to respond to two prior vaccine doses",
        "Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab",
        "Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia",
        "Assessment of serology after Sars-Cov-2 vaccine in allogeneic HCT recipients",
        "Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation",
        "Anti CD20-based immunochemotherapy abolishes antibody response to Covid-19 mRNA vaccine in lymphoma patients vaccinated during active first line treatment",
        "T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial",
        "Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer",
        "COVID-19 vaccine responsiveness in patients with multiple myeloma and Waldenstr\u00f6m macroglobulinemia",
        "Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas",
        "Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients",
        "Should be a third dose of BNT162b2 mRNA COVID-19-vaccine administered in patients with myelofibrosis under ruxolitinib?",
        "COVID-19 vaccination in cancer patients older than 70 years undergoing active treatment. Seroconversion rate and safety",
        "Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia",
        "A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia",
        "Humoral immunity and adverse events after vaccination against COVID-19 by a vector based vaccine Sputnik V in patients with chronic myeloid leukemia",
        "Short research communication anti-spike antibody response to COVISHIELD\u2122 (SII-ChAdOx1 nCoV-19) vaccine in patients with B-cell and plasma cell malignancies and hematopoietic cell transplantation recipients",
        "Humoral responses after SARS-CoV-2 mRNA vaccination and breakthrough infection in cancer patients",
        "Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors",
        "SARS-CoV-2 T-cell responses in allogeneic hematopoietic stem cell recipients following two doses of BNT162b2 mRNA vaccine",
        "Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: The Italian VAX4FRAIL study",
        "Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia",
        "COVID-19 vaccination: evaluation of risk for protection failure in chronic lymphocytic leukemia patients",
        "Immunogenicity of Sars-Cov-2 mRNA 1273 vaccine in patients with lymphoid malignancies",
        "Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination",
        "Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma",
        "Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy",
        "Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine",
        "Lymphocytopenia and anti-CD38 directed treatment impact the serological SARS-CoV-2 response after prime boost vaccination in patients with multiple myeloma",
        "Evaluation of antibody response to SARS-CoV-2 mRNA-1273 vaccination in patients with cancer in Florida",
        "Determinants of COVID-19 vaccine response in patients with lymphoma on B cell directed therapy",
        "Poor humoral responses to mRNA vaccines against SARS-CoV-2 in patients after CAR-T-cell therapy",
        "COVID vaccine antibody responses in patients with hematologic malignancies in a myeloid enriched cohort: a better antibody response in patients with myeloid malignancies than B-cell malignancies",
        "Sars-Cov-2 antibody levels in blood cancer patients after a third Sars-Cov-2 \u201cBooster\u201d vaccination - observational data from the LLS National Registry",
        "Antibody response to COVID-19 mRNA vaccines in oncologic and hematologic patients undergoing chemotherapy",
        "Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies",
        "Sars-CoV2 antibody responses in patients with hematological malignancies following anti-CD20 therapy",
        "Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients",
        "Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 vaccination in the immunocompromised study (COVICS)",
        "Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib",
        "Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study",
        "Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia",
        "Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination",
        "A clue to better select chronic lymphocytic leukemia patients with optimal response to BNT162b2 mRNA COVID-19 vaccine",
        "Adequate antibody response to COVID-19 vaccine in patients with monoclonal gammopathies and light chain amyloidosis",
        "Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients",
        "Antibody immunoresponse to antiSars-COV2 vaccine in cancer patients",
        "Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients",
        "Antibody response to COVID-19 vaccination in patients with lymphoma",
        "Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation",
        "Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases",
        "Anti-spike (S) antibody production post Covid-19 vaccination after B cell depleting therapy (BCDT) for Non-Hodgkin Lymphoma (NHL)",
        "Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment",
        "B cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation",
        "B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders",
        "Impaired antibody response following the second dose of the BNT162b2 vaccine in patients with myeloproliferative neoplasms receiving ruxolitinib",
        "Impaired antibody response after mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia",
        "Cellular immune responses to BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia",
        "Immunogenicity of COVID-19 mRNA vaccines in patients with lymphoid malignancies",
        "Responses to Sars-Cov-2 vaccines in patients with myelodysplastic syndrome and acute myeloid leukemia",
        "Response to COVID-19 vaccines in patients receiving intensified post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) due to ultra-high risk (UHiR) newly diagnosed myeloma (NDMM) or primary plasma cell leukemia (pPCL): exploratory analysis of the UK optimum/muknine trial",
        "Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies",
        "Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients",
        "Two Doses of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral response and serological conversion predictors",
        "Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy",
        "CD20-targeted therapy ablates De Novo antibody response to vaccination but spares preestablished immunity",
        "Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: an observational cohort study",
        "COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience",
        "Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma",
        "High humoral response after anti-Sars-Cov-2 mRNA-based vaccines in patients with active multiple myeloma (MM) and relationship with disease status/line of therapy",
        "SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia",
        "T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies",
        "Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin\u2019s lymphomas",
        "Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning",
        "The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2",
        "Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma",
        "Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients",
        "Incidence and predictors of Sars-Cov-2 antibody responses following COVID-19 vaccination in allogeneic stem cell transplant recipients",
        "COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA",
        "COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity",
        "COVID-19 vaccine responses in patients with plasma cell dyscrasias after complete vaccination",
        "Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer",
        "Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response",
        "Evaluation of antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunizations in patients with B-cell malignancies",
        "Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response",
        "Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies",
        "Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation",
        "Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia",
        "Serologic responses to COVID-19 vaccines in hematological patients are predominantly impaired in lymphoid but not in myeloid malignancies",
        "Quantitative analysis of SARS-CoV-2 antibody status between patients with cancer and healthy individuals with extended vaccination dosing intervals in Canada",
        "Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines",
        "Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response",
        "Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies",
        "Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstr\u00f6m macroglobulinaemia: a French Innovative Leukaemia Organization study",
        "Serologic responses following Sars-Cov-2 vaccination and factors influencing it in patients with hematological malignant and non-malignant diseases: a prospective multicentric study",
        "The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia",
        "SARS-CoV-2 vaccine responses following CD20-depletion treatment in patients with haematological and rheumatological disease: a West Midlands Research Consortium study",
        "Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study",
        "Immunogenicity of COVID-19 vaccinations in hematological patients: 6-month follow-up and evaluation of a 3rd vaccination",
        "The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients",
        "Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients",
        "Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination",
        "Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study",
        "Sars-Cov-2 antibody decay monitoring in mRNA vaccinated multiple myeloma patients",
        "Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy-a single-center prospective cohort study",
        "Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma",
        "Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres",
        "Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies",
        "Real-world third COVID-19 vaccine dosing and antibody response in patients with hematologic malignancies",
        "Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19",
        "Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab",
        "The effect of rituximab on vaccine responses in patients with immune thrombocytopenia",
        "Surface antibody (Anti-HBs) kinetics during rituximab chemotherapy and performance of hepatitis B vaccine before immunosuppression: two prospective studies",
        "Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease",
        "JAK inhibition impairs NK cell function in myeloproliferative neoplasms",
        "Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease",
        "Infection and immunity in chronic lymphocytic leukemia",
        "Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of Covid-19",
        "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection",
        "Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis",
        "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization",
        "mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}